Compare FDP & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | IMCR |
|---|---|---|
| Founded | 1886 | 2008 |
| Country | Cayman Islands | United Kingdom |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1999 | 2016 |
| Metric | FDP | IMCR |
|---|---|---|
| Price | $41.83 | $31.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $61.82 |
| AVG Volume (30 Days) | 264.5K | ★ 392.3K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $4,322,300,000.00 | $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | $3.14 | $8.21 |
| P/E Ratio | $22.75 | ★ N/A |
| Revenue Growth | 0.98 | ★ 43.05 |
| 52 Week Low | $30.92 | $26.37 |
| 52 Week High | $43.58 | $40.71 |
| Indicator | FDP | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 47.50 |
| Support Level | $39.86 | $28.90 |
| Resistance Level | $43.30 | $31.65 |
| Average True Range (ATR) | 1.32 | 1.16 |
| MACD | 0.06 | 0.24 |
| Stochastic Oscillator | 65.10 | 51.40 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.